


產品信息
| 名稱 | HT-29 (人結腸癌細胞) (STR鑒定正確) |
| 別稱 | HT 29; HT29 |
| 背景描述 | HT-29細胞是由J·Fogh在1964年用移植培養方法和含15%FBS的F12培養液從原發性腫瘤分離的;近來,已建株的培養細胞用含相同血清McCoy's5A培液培養。HT-29細胞在裸鼠中致瘤,也能在類固醇處理的地鼠中致瘤。HT-29細胞合成IgA、CEA、蛋白綁定TGF-β的分泌成分和粘液素等。 |
| 種屬 | 人 |
| 年齡(性別) | 女;44歲 |
| 組織來源 | 結直腸腺癌 |
| 生長特性 | 貼壁細胞 |
| 細胞形態 | 上皮細胞樣 |
| 細胞類型 | 腫瘤細胞 |
| 腫瘤類型 | 腸癌細胞 |
| 生物安全等級 | 1 |
| 生長培養基 | McCoy’s 5A+10% FBS+1% P/S |
| 推薦傳代比例 | 1:3-1:4 |
| 推薦換液頻率 | 2~3次/周 |
| 倍增時間 | ~36-60 hours |
| 凍存條件 | 凍存液:55% 基礎培養基+40%FBS+5%DMSO溫度:液氮 |
| 培養條件 | 氣相:空氣,95%;CO2,5%溫度:37℃ |
| 致瘤性 | Yes, in nude mice; forms well differentiated adenocarcinoma consistent with colonic primary (grade I); tumors also form in steroid treated hamsters. |
| 受體表達情況 | human adrenergic alpha2A, urokinase receptor (u-PAR), vitamin D (moderate expression), urokinase receptor (u-PAR); vitamin D (moderate expression), human adrenergic alpha2A |
| 基因表達情況 | secretory component of IgA; carcinoembryonic antigen (CEA); transforming growth factor beta binding protein; mucin, myc+; ras+; myb+; fos+; sis+; p53+; abl -; ros -; src -, Blood Type A; Rh+; HLA A1, A3, B12, B17, Cw5, HT-29 cells are negative for CD4, but there is cell surface expression of galactose ceramide (a possible alternative receptor for HIV). |
| 保藏機構 | ATCC; HTB-38 BCRJ; 0111 CCLV; CCLV-RIE 0960 DSMZ; ACC-299 ECACC; 91072201 |
STR位點信息
| Amelogenin | X |
| CSF1PO | 11,12 |
| D2S1338 | 19,23 |
| D3S1358 | 15,17 |
| D5S818 | 11,12 |
| D7S820 | 10 |
| D8S1179 | 10,16 |
| D13S317 | 11,12 |
| D16S539 | 11,12 |
| D18S51 | 13 |
| D19S433 | 14 |
| D21S11 | 29,30 |
| FGA | 20,22 |
| PentaD | 11,13 |
| PentaE | 14,16 |
| TH01 | 6,9 |
| TPOX | 8,9 |
| vWA | 17,19 |
| D6S1043 | 12,14 |
| D12S391 | 18.3,21 |
| D2S441 | 11 |